986 results about "P phosphate" patented technology

A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:

wherein

• [0001]
  • Base is a purine or pyrimidine base;
  [0002]
  • R¹ is OH, H, OR³, N₃, CN, halogen, including F, or CF₃, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;
  [0003]
  • R² is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R² is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and
  [0004]
  • R³ is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and/or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid/dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

Phosphorus-based coatings having a plurality of phosphate moieties, a plurality of phosphonate moieties, or both, covalently bonded to an oxide surface of an implantable substrate exhibiting one or more of the following characteristics: (a) the surface phosphorus-containing group density of the coated regions of the substrate is at least about 0.1 nmol/cm²; (b) the phosphorus-based coating has a thickness of less than about 10 nm; or (c) the surface phosphorus-containing group density of the coated regions of the substrate is equal to or greater than the surface hydroxyl group density of the oxide surface of the substrate. Implantable devices embodying the coated substrates are also disclosed.

The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and/or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid/dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

A flame retardant composition includes, as essential components having two specified types of phosphate compounds; silicon dioxide or metal oxides; and at least one member selected from among higher aliphatic carboxylic acids, metal salts of higher aliphatic carboxylic acid, higher fatty acid amide compounds, and esters between mono- or polyhydric alcohols and higher aliphatic carboxylic acids. This flame retarder composition is free from secondary agglomeration, and does not need incorporation of a halogenated flame retarder that when blended in a synthetic resin, releases harmful gas at combustion. The flame retardant composition enables imparting flame retardant properties to synthetic resins with the use of a small amount of flame retarder.

This invention relates to waterborne coating compositions having improved compatability with metal pigments, i.e., improved shelf life and reduced gassing and gellation. The compositions comprise at least one aqueous dispersion of (1) at least one emulsion copolymer polymerized from (a) at least one ethylenically unsaturated anionic monomer and (b) at least one other olefinically unsaturated monomer, said copolymer being made using at least one phosphate surfactant having at least one phosphorus acid group or salt thereof, said copolymer being crosslinked, and (2) at least one non-water soluble metal pigment. The compositions are useful in paints and other coatings.

The present invention relates to compositions and methods employing 5′-phosphate-dependent nucleic acid exonucleases. In particular, the present invention provides kits and methods employing 5′-phosphate-dependent nucleic acid exonucleases for selective enrichment, isolation and amplification of a particular set of desired nucleic acid molecules from samples that also contain undesired nucleic acid molecules for a variety of uses. In preferred embodiments, the desired nucleic acid molecules comprise prokaryotic and/or eukaryotic mRNA.

The invention relates to a chitosan modified alginate hydrogel three-dimensional porous bracket with specific in-vitro degradability and a preparation method thereof. The method comprises the following steps: dissolving sodium alga acid serving as a raw material in phosphate buffer solution; performing amidation reaction of a carboxyl group in the sodium alga acid and an amino group in a cross-linking agent cystamine or dimethyl cystinate under the activation of water-soluble carbodiimide to form a chemically crosslinked hydrogel; performing freeze drying on the hydrogel to obtain a porous bracket material of the hydrogel; and performing surface modification on the porous bracket by using chitosan. In solution of a reducing agent such as cysteine with an appropriate concentration, a disulfide bond in a hydrogel cross-bridge is degraded through a disulfide bond-sulfydryl conversion reaction, so the porous bracket is decomposed and dissolved and disappears. Therefore, the porous bracket can be used as an in-vitro cell culture template material. The hydrogel porous bracket researched by the invention has the characteristics of simple preparation, rich raw material source, low cost and availability. Various physiochemical performances, mechanical strength, degradation rate and surface properties of the bracket material are controllable within a large range.

Methods for forming proppant pillars in a formation during formation fracturing include include periods of pumping a first fracturing fluid including a proppant and an aggregating composition including a reaction product of a phosphate compound or a plurality of phosphate and an amine, periods of pumping a second fracturing fluid excluding a proppant and an aggregating composition including a reaction product of a phosphate compound and periods of pumping a third fracturing fluid including an aggregating composition including a reaction product of a phosphate compound, where the pumping of the three fracturing fluids may be in any order and may involve continuous pumping, pulse pumping, or non-continuous pumping.

An aqueous hydrogen peroxide solution for use in disinfectants, soaps, shower gels, and mouth rinses is provided, with improved disinfectant and anti-microbial activity. The solutions contain at least one phosphorus based acid compound, e.g. phosphoric and/or a phosphonate and a cationic or non-ionic surfactant. Importantly, the solutions do not require the presence of an anionic surfactant to achieve the objects of the invention, thus enabling successful manufacturing using multiple formulation methods. The solution may also contain fragrances, degreasers, flavors, or other additives depending on the purposes and intended functions of the solutions.

The invention discloses drug-carrying liposome co-modified by folic acid and TAT peptide and a preparation method thereof. The drug-carrying liposome comprises liposome, a long chain targeted membrane material, a short chain targeted membrane material and a drug. Meanwhile, the invention provides the preparation method of the drug-carrying liposome co-modified by folic acid and TAT peptide. The method comprises the following steps: weighing phospholipid, cholesterol, the long chain targeted membrane material, the short chain targeted membrane material and the drug, dissolving the components in an organic solvent, and then carrying out rotary evaporation at 50 DEG C under reduced pressure to remove the organic solvent so as to obtain a medicated liposome membrane; adding a phosphate buffer solution into the medicated liposome membrane for dissolving, carrying out ultrasonic treatment for 2 minutes, and filtering for 10 times by using a 0.22mu m membrane to obtain double-target drug-carrying liposome. According to the drug-carrying liposome disclosed by the invention, the TAT peptide is connected with specific ligands by means of PEG with different weight-average molecular weights to establish a nanometer carrier modified by double ligands, and the prepared drug-carrying liposome can be used for efficiently conveying the drug in tumor cells.

Compositions and methods for forming, in an aqueous environment, a nanoaggregate of calcium fluoride and amorphous calcium phosphate-containing compound, such as amorphous calcium phosphate fluoride or amorphous calcium carbonate phosphate fluoride are described. The nanoaggregate (or nanocomposite) can release calcium, phosphate, and fluoride, and ultimately convert to the tooth mineral, fluorapatite. One method for forming such a nanoaggregate involves applying a non-aqueous (e.g., varnish-based) composition (e.g., a suspension), containing solid particles of water soluble salts of calcium, phosphate, and fluoride, to the aqueous environment of the mouth. This results in rapid solubilization of the salts, precipitation of the nanoaggregate, and tooth remineralization. Tooth fluoridation and remineralization may also be carried out by applying to the tooth a non-aqueous carrier containing the nanoaggregate. Whitening agents can also be added to these compositions and methods.

The invention discloses a magnesium base degradable implant material, belonging to the technical field of biological materials. The implant material is composed of Mg-Zn-Zr alloy matrix and micro-arc oxidation coating; the micro-arc oxidation coating is formed by micro-arc oxidation treatment by electrolyte formed by solving the sodium silicate, potassium hydroxide, potassium fluoride, soluble phosphate and trolamine in pure water; each liter of electrolyte contains 12-18g of sodium silicate, 3-8g of potassium hydroxide, 2-7g of potassium fluoride, 5-20g of soluble phosphate and 5-10ml of trolamine. The implant material has not only high micro hardness but also excellent decay resistance; and after dipping in simulated body fluid, the surface has phosphorite deposition, which shows that the material has certain biological activity.

The present invention relates to self-setting compositions consisting in admixed liquid and solid components enable the formation of hardened bio-materials having a broad range of properties and performances. The present invention proposes a) a thermo-sensitive self-gelling liquid component, being water-based, comprising at least a polycationic and a phosphate source, wherein the liquid component is a thermo-gelling solution at a pH ranging from 6.5 to 7.4; b) a powder component consisting in at least two calcium phosphate sources. The preferred calcium phosphate source includes apatites, tricalcium phosphates, tetracalcium phosphates and dicalcium phosphates. Both solid and liquid components are admixed to form a flowable slurry that sets in situ into a hardened calcium phosphate based bio-material.